Lamotrigine Extended-Release Tablets

Type of Posting	Revision Bulletin
Posting Date	18–Nov–2016
Official Date	01–Dec–2016
Expert Committee	Chemical Medicines Monographs 4
Reason for Revision	Compliance

In accordance with the Rules and Procedures of the 2015-2020 Council of Experts, the Chemical Medicines Monographs 4 Expert Committee has revised the Lamotrigine Extended-Release Tablets monograph. The purpose for the revision is to add *Dissolution Test 2* for drug products approved by the FDA with different conditions and tolerances than the existing dissolution tests. This test was validated using an Xterra RP-8 brand of 4.6-mm x 15-cm, 5-µm packing L7 column manufactured by Waters.

Additionally, minor editorial changes have been made to update the monograph to current *USP* style.

The Lamotrigine Extended-Release Tablets Revision Bulletin supersedes the currently official Lamotrigine Extended-Release Tablets monograph. The Revision Bulletin will be incorporated in the *Second Supplement* to *USP 40–NF 35*.

Should you have any questions, please contact Ren-Hwa Yeh, Ph.D., Senior Scientific Liaison, (301–998–6818 or RHY@usp.org).